// App-Quantinova.ai

P1029 : MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

Researchers

Presenter

  • Vikas Gupta

Principal Investigators

  • John Mascarenhas

  • Marina Kremyanskaya

  • Moshe Talpaz

  • Jean-Jacques Kiladjian

  • Alessandro Vannucchi

  • Srdan Verstovsek

  • Gozde Colak

  • Debarshi Dey

  • Claire Harrison

Medical Centers

  • Constellation Pharmaceut

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • MorphoSys AG, Planegg, Germany

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Hôpital Saint-Louis, Université de Paris, INSERM,Paris,Frankrijk

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Univer

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • The Tisch Cancer Institute, Icahn Sc

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • MorphoSys AG,Planegg,Deutschland

  • University of Texas MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • MorphoSys AG,Planegg,Deutschland

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • MorphoSys AG,Planegg,Deutschland

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • MorphoSys AG,Planegg,Германия

  • University of Texas MD Anderson Cancer Center,Houston,Stati Uniti

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,New York,Vereinigte Staaten

  • MorphoSys AG, Planegg, Germany

  • Guy's and St

  • MorphoSys AG,Planegg,Allemagne

  • The University of Texas MD Anderson Cancer...

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • MorphoSys AG,Planegg,Allemagne

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • MorphoSys AG,Planegg,Allemagne

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Princess Margaret Cancer Centre and University of Toronto,...

  • Hôpital Saint

  • University of Michigan Comprehensive Cancer Center,Ann Arbor, MI,Vereinigte Staaten

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Leukemia,The University of Texas MD Anderson Cancer Center,HOUSTON,Estados Unidos

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Locations

  • Canada

  • United States

  • France

  • Italy

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyurea

  • Ruxolitinib phosphate

  • Fedratinib

  • CPI-0610

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • III

Study Id's

  • NCT02158858

  • NCT04603495

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved